Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 14, 2006, Pages 3784-3788

  Watson, Nigel S ^a   Brown, David ^a   Campbell, Matthew ^a   Chan, Chuen ^a   Chaudry, Laiq ^a   Convery, Máire A ^a   Fenwick, Rebecca ^a   Hamblin, J Nicole ^a   Haslam, Claudine ^a   Kelly, Henry A ^a   King, N Paul ^a   Kurtis, Cynthia L ^b   Leach, Andrew R ^a   Manchee, Gary R ^a   Mason, Andrew M ^a   Mitchell, Charlotte ^a   Patel, Champa ^a   Patel, Vipulkumar K ^a   Senger, Stefan ^a   Shah, Gita P ^a   Weston, Helen E ^a   Whitworth, Caroline ^a   Young, Robert J ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Factor Xa

Indexed keywords

AMIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; N 2 (MORPHOLIN 4 YL) 2 OXOETHYL DERIVATIVE; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBIN III; BIOLOGICAL AVAILABILITY; FIBRINOLYTIC AGENTS; MALE; PYRROLIDINONES; RATS; RATS, WISTAR; THROMBIN;

CANIS FAMILIARIS;

EID: 33746486222     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.053     Document Type: Article

References (27)

1. Colman R.W., Clowes A.W., George J.N., Hirsh J., and Marder V.J. Hemostasis and Thrombosis: Basic Principles and Clinical Practice (2001), Lippincott, Williams and Wilkins, Philadelphia (Chapter 1)
2. Pass M., Abu-Rabie S., Baxter A., Conroy R., Coote S.J., Craven A.P., Finch H., Hindley S., Kelly H.A., Lowdon A.W., McDonald E., Mitchell W.L., Pegg N.A., Procopiou P.A., Ramsden N.G., Thomas R., Walker D.A., Watson N.S., Jhoti H., Mooney C.J., Tang C.-M., Thomas P.J., Parry S., and Patel C. Bioorg. Med. Chem. Lett. 9 (1999) 1657 and references therein
3. Sanderson P.E.J., and Naylor-Olsen A.M. Curr. Med. Chem. 5 (1998) 289
4. Coburn C.A. Exp. Opin. Ther. Patents 11 (2001) 721
5. Steinmetzer T., and Sturzebecher J. Curr. Med. Chem. 11 (2004) 2297
6. Quan M.L., and Smallheer J.M. Curr. Opin. Drug Discovery Dev. 7 (2004) 460
7. Gould W.R., and Leadley R.J. Curr. Pharm. Des. 9 (2003) 2337
8. Ewing, W. R.; Becker, M. R.; Pauls, H. W.; Cheney, D. L.; Mason, J. S.; Spada, A. P.; Choi-Sledeski, Y. M. WO 9640679 A1, 1996.
9. Ewing W.R., Becker M.R., Manetta V.E., Davis R.S., Pauls H.W., Mason H., Choi-Sledeski Y.M., Green D., Cha D., Spada A.P., Cheney D.L., Mason J.S., Maignan S., Guilloteau J.-P., Brown K., Colussi D., Bentley R., Bostwick J., Kasiewski C.J., Morgan S.R., Leadley R.J., Dunwiddie C.T., Perrone M.H., and Chu V. J. Med. Chem. 42 (1999) 3557
10. fXa inhibitory activities were determined using N-α-Z-d-Arg-Gly-Arg-p-nitroanilide as chromogenic substrate; details are described in Ref. 11.
11. Anticoagulant activities were determined in the prothrombin time (PT) assay; details (test 2) are described in Ref. 11
12. Macdonald S.J.F., Clarke G.D.E., Dowle M.D., Harrison L.A., Hodgson S.T., Inglis G.G.A., Johnson M.R., Shah P., Upton R.J., and Walls S.B. J. Org. Chem. 64 (1999) 5166
13. Compounds 13a and 13b were prepared as racemates from the corresponding diastereomeric intermediates 16 which were separated by chromatography; the relative stereochemistry of the diastereomers 13a and 13b have not been determined.
14. 2-Azido-4-iodobutanoate was derived from the 4-bromo derivative by reaction with sodium iodide in acetone; 2-azido-4-bromobutanoate was prepared from the 2,4-dibromo derivative (Ref. 9b) by the method reported for the corresponding methyl ester. J. Org. Chem. 47 (1982) 1319
15. Wasserman H.H., Lipshutz B.H., Tremper A.W., and Wu J.S. J. Org. Chem. 46 (1981) 2991
16. Compounds 21-22 were derived by deprotection of the corresponding Boc-protected derivatives by treatment with TFA in DCM. Compound 23 was prepared as a 1:1 mixture of two diastereomers by the route outlined in Scheme 2 utilising the tert-butyl ester of l-alanine.
17. Chan, C.; Hamblin, J. N.; Kelly, H. A.; King, N. P.; Mason, A. M.; Patel, V. K.; Senger, S.; Shah, G. P.; Watson, N. S.; Weston, H. E.; Whitworth, C.; Young, R. J. WO 02100886 A1, 2002.
18. Chan, C.; Hamblin, J. N.; Kelly, H. A.; King, N. P.; Mason, A. M.; Patel, V. K.; Senger, S.; Shah, G. P.; Watson, N. S.; Weston, H. E.; Whitworth, C.; Young, R. J. WO 02100830 A1, 2002.
19. Valko K., Du C.M., Bevan C., Reynolds D.P., and Abraham M.H. Curr. Med. Chem. 8 (2001) 1137
20. Compound 21 shows good selectivity over other trypsin-like serine proteases tested, including thrombin.
21. Chan, C. et al. J. Med. Chem., manuscript in preparation.
22. Senger, S. et al. Bioorg. Med. Chem. Lett., manuscript in preparation.
23. free of 0.242. Coordinates are deposited in the protein data bank with code 2cji.
24. Similar findings have been reported recently for other series of fXa inhibitors. Choi-Sledeski Y.M., Kearney R., Poli G., Pauls H., Gardner C., Gong Y., Becker M., Davis R., Spada A., Liang G., Chu V., Brown K., Collussi D., Leadley Jr. R., Rebello S., Moxey P., Morgan S., Bentley R., Kasiewski C., Maignan S., Guilloteau J.-P., and Mikol V. J. Med. Chem. 46 (2003) 681
25. Jia Z.J., Su T., Zuckett J.F., Wu Y., Goldman E.A., Li W., Zhang P., Clizbe L.A., Song Y., Bauer S.M., Huang W., Woolfrey J., Sinha U., Arfsten A.E., Hutchaleelaha A., Hollenbach S.J., Lambing J.L., Scarborough R.M., and Zhu B.-Y. Bioorg. Med. Chem. Lett. 14 (2004) 2073
26. Roehrig S., Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.-H., Reinemer P., and Perzborn E. J. Med. Chem. 48 (2005) 5900
27. Compound 24 was administered iv (1 mg/kg) as a slow bolus over 5 min and po (1 mg/kg) via gavage to female Beagle dogs. The dosing vehicle was a 5:95% (v/v) mixture of DMSO and 50:50 PEG-200:sterile water.